CAPAFOUR

CAPAFOUR

In 2021, Cantargia initiated a third clinical study, the Phase Ib study CAPAFOUR, to evaluate nadunolimab in combination with the chemotherapy regimen FOLFIRINOX for the first-line treatment of metastatic pancreatic cancer (PDAC).

The primary objective of the study was safety, and secondary objectives included effects on biomarkers and anti-tumor activity.

The initial safety part with different doses was completed successfully. The design allowed for frequent dose reductions, which limits the possibilities to draw conclusions about treatment effect.

A total of 18 patients were included in the study who were terminated prematurely due to strategic prioritization.

In CAPAFOUR, an association was observed between higher doses of nadunolimab and lower incidence and later onset of CIPN, in line with data from the CANFOUR and CESTAFOUR studies, providing further support for the potential neuroprotective role of nadunolimab.

Read more about CAPAFOUR on ClinicalTrials.gov (NCT04990037).